Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD)

European Journal of Pharmacology

Volumn 788, Issue , 2016, Pages 306-314

  Araújo, Shyrlene ^a,b   Soares e Silva, Amanda ^a,b   Gomes, Fabiana ^a,b   Ribeiro, Edlene ^a,b   Oliveira, Wilma ^a,b   Oliveira, Amanda ^a,b   Lima, Ingrid ^a,b   Lima, Maria do Carmo ^b   Pitta, Ivan ^b   Peixoto, Christina ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

AMPK and SREBP 1c; LPSF GQ 02; NAFLD; PPAR ; Thiazolidinediones

Indexed keywords

5 (4 CHLOROBENZYLIDENE) 3 (4 METHYLBENZYL)THIAZOLIDINE 2,4 DIONE; ACETYL COENZYME A CARBOXYLASE; ADIPOSE TRIGLYCERIDE LIPASE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER X RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5-(4-CHLOROBENZYLIDENE)-3-(4-METHYLBENZYL)THIAZOLIDINE-2,4-DIONE; FATTY ACID SYNTHASE; PNPLA2 PROTEIN, MOUSE; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FATTY LIVER; GENE CONTROL; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIVER; LIVER CELL; LIVER METABOLISM; MALE; MICROSCOPY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING; AGONISTS; ANIMAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; FATTY ACID SYNTHASES; FORKHEAD BOX PROTEIN O1; HEPATOCYTES; LIPASE; LIPID METABOLISM; LIPOLYSIS; LIVER; MALE; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; PPAR ALPHA; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; THIAZOLIDINEDIONES;

EID: 84978194753     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.06.043     Document Type: Article

References (32)

1. Ahmed, W., Ziouzenkova, O., Brown, J., Devchand, P., Francis, S., Kadakia, M., Kanda, T., Orasanu, G., Sharlach, M., Zandbergen, F., Plutzky, J., PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?. J. Intern. Med. 262 (2007), 184–198, 10.1111/j.1365-2796.2007.01825.x.
2. Auguet, T., Berlanga, A., Guiu-Jurado, E., Porras, J.A., Molecular pathways in non-alcoholic fatty liver disease. Clin. Exp. Gastroenterol., 2014, 221, 10.2147/CEG.S62831.
3. Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976), 248–254 http://dx.doi.org/10.1016/0003-2697(76)90527-3.
4. Chang, E., Park, C.-Y., Park, S.W., Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J. Diabetes Investig. 4 (2013), 517–524, 10.1111/jdi.12107.
5. Chen, W., Chen, Y., Chiang, Y., Wang, S., Lee, H., Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway. Biochem. Pharmacol. 84 (2012), 522–531, 10.1016/j.bcp.2012.05.022.
6. Chen, W., Wei, H., Chiu, W., Kang, C., Lin, T., Hung, C., Chen, M., Shieh, M., Lee, C., Lee, H., Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens. Eur. J. Pharmacol. 671 (2011), 107–112, 10.1016/j.ejphar.2011.09.029.
7. Deng, X., Zhang, W., O-Sullivan, I., Williams, J.B., Dong, Q., Park, E.A., Raghow, R., Unterman, T.G., Elam, M.B., FoxO1 inhibits Sterol Regulatory Element-binding Protein-1c (SREBP-1c) gene expression via transcription factors Sp1 and SREBP-1c. J. Biol. Chem. 287 (2012), 20132–20143, 10.1074/jbc.M112.347211.
8. Foufelle, F., Ferr, P., Hepatic steatosis : a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 12 (2010), 83–92, 10.1111/j.1463-1326.2010.01275.x.
9. Gawrieh, S., Chalasani, N., Pharmacotherapy for nonalcoholic fatty liver disease. Semin. Liver Dis. 35 (2015), 338–348, 10.1055/s-0035-1562951.
10. Gupte, A.A., Liu, J.Z., Ren, Y., Minze, L.J., Wiles, J.R., Collins, A.R., Lyon, C.J., Pratico, D., Finegold, M.J., Wong, S.T., Webb, P., Baxter, J.D., Moore, D.D., Hsueh, W.A., Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 52 (2010), 2001–2011, 10.1002/hep.23941.
11. Han, J.Y., Park, S.H., Yang, J.H., Kim, M.G., Cho, S.S., Yoon, G., Cheon, S.H., Ki, S.H., Licochalcone suppresses LXRα-induced hepatic lipogenic gene expression through AMPK/sirt1 pathway activation. Toxicol. Res. 30 (2014), 19–25, 10.5487/TR.2014.30.1.019.
12. Higuchi, N., Kato, M., Shundo, Y., Tajiri, H., Tanaka, M., Yamashita, N., Kohjima, M., Kotoh, K., Nakamuta, M., Takayanagi, R., Enjoji, M., Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 38 (2008), 1122–1129, 10.1111/j.1872-034X.2008.00382.x.
13. Huang, Y.Y., Gusdon, A.M., Qu, S., Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies. Lipids Health Dis., 12, 2013, 171, 10.1186/1476-511X-12-171.
14. Kanuri, G., Bergheim, I., In vitro and in vivo models of Non-Alcoholic Fatty Liver Disease (NAFLD). Int. J. Mol. Sci. 14 (2013), 11963–11980, 10.3390/ijms140611963.
15. Kim, Y.W., Kim, Y.M., Yang, Y.M., Kim, T.H., Hwang, S.J., Lee, J.R., Kim, S.C., Kim, S.G., Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis. Free Radic. Biol. Med. 48 (2009), 567–578, 10.1016/j.freeradbiomed.2009.12.006.
16. Larter, C.Z., Yeh, M.M., Van Rooyen, D.M., Brooling, J., Ghatora, K., Farrell, G.C., Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 27 (2012), 341–350, 10.1111/j.1440-1746.2011.06939.x.
17. Lee, M.S., Kim, D., Jo, K., Hwang, J.K., Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice. Biochem. Biophys. Res. Commun. 401 (2010), 92–97, 10.1016/j.bbrc.2010.09.016.
18. Lefebvre, P., Sorting out the roles of PPAR in energy metabolism and vascular homeostasis. J. Clin. Investig. 116 (2006), 571–580, 10.1172/JCI27989.
19. Mourão, R.H., Silva, T.G., Soares, a L.M., Vieira, E.S., Santos, J.N., Lima, M.C. a, Lima, V.L.M., Galdino, S.L., Barbe, J., Pitta, I.R., Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones. Eur. J. Med. Chem. 40 (2005), 1129–1133, 10.1016/j.ejmech.2005.06.002.
20. Nakatani, T., Katsumata, A., Miura, S., Kamei, Y., Ezaki, O., Effects of fish oil feeding and fasting on LXRα/RXRα binding to LXRE in the SREBP-1c promoter in mouse liver. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1736 (2005), 77–86, 10.1016/j.bbalip.2005.07.003.
21. Quan, H.Y., Kim, D.Y., Kim, S.J., Jo, H.K., Kim, G.W., Chung, S.H., Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochem. Pharmacol. 85 (2013), 1330–1340, 10.1016/j.bcp.2013.02.007.
22. Seo, M.S., Kim, J.H., Kim, H.J., Chang, K.C., Park, S.W., Honokiol activates the LKB1 – AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes. Toxicol. Appl. Pharmacol. 284 (2015), 113–124, 10.1016/j.taap.2015.02.020.
23. Soares e Silva, A.K., de Oliveira Cipriano Torres, D., dos Santos Gomes, F.O., dos Santos Silva, B., Lima Ribeiro, E., Costa Oliveira, A., dos Santos, L.A.M., de Lima, M.D.C.A., Pitta, I.D.R., Peixoto, C.A., LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). PLoS One, 10, 2015, e0123787, 10.1371/journal.pone.0123787.
24. Stanković, M.N., Mladenović, D.R., Đuričić, I., Šobajić, S.S., Timić, J., Jorgačević, B., Aleksić, V., Vučević, D.B., Ješić-Vukićević, R., Radosavljević, T.S., Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease. Arch. Med. Res. 45 (2014), 116–124, 10.1016/j.arcmed.2013.12.010.
25. Tessari, P., Coracina, A., Cosma, A., Tiengo, A., Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 19 (2009), 291–302, 10.1016/j.numecd.2008.12.015.
26. Tilg, H., Moschen, A.R., Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52 (2010), 1836–1846, 10.1002/hep.24001.
27. Tong, L., Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell. Mol. Life Sci. 62 (2005), 1784–1803, 10.1007/s00018-005-5121-4.
28. Varas-Lorenzo, C., Margulis, A.V., Pladevall, M., Riera-Guardia, N., Calingaert, B., Hazell, L., Romio, S., Perez-Gutthann, S., The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc. Disord., 14, 2014, 129, 10.1186/1471-2261-14-129.
29. Wang, Y., Wu, Z., Li, D., Wang, D., Wang, X., Feng, X., Xia, M., Involvement of oxygen-regulated protein 150 in AMP-activated protein kinase-mediated alleviation of lipid-induced endoplasmic reticulum stress. J. Biol. Chem. 286 (2011), 11119–11131, 10.1074/jbc.M110.203323.
30. Yang, Y., Li, W., Liu, Y., Sun, Y., Li, Y., Yao, Q., Li, J., Zhang, Q., Gao, Y., Gao, L., Zhao, J., Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxO1 and Nrf2 via the SIRT1/LKB1/AMPK pathway. J. Nutr. Biochem. 25 (2014), 1207–1217 doi:10.1016/j.jnutbio.2014.06.001.
31. Yang, J., Craddock, L., Hong, S., Liu, Z.M., AMP-activated protein kinase suppresses LXR-dependent sterol regulatory element-binding protein-1c transcription in rat hepatoma McA-RH7777 cells. J. Cell. Biochem. 106 (2009), 414–426, 10.1002/jcb.22024.
32. Zhang, T., Yamashita, Y., Yasuda, M., Yamamoto, N., Ashida, H., Ashitaba (Angelica keiskei) extract prevents adiposity in high-fat diet-fed C57BL/6 mice. Food Funct. 6 (2015), 135–145, 10.1039/c4fo00525b.